With much interest we read the article by Susan J. Kies et al.  regarding patients with congenital long QT syndrome (LQTS). We congratulate the authors on their excellent review but would like to discuss several aspects. As stated in the introduction, patients with LQTS often show a “delayed cellular repolarization and heterogeneity in dispersion of repolarization, which … can lead to early after-depolarization, further dispersion of repolarization, and the formation of reentry circuits.”

It becomes increasingly apparent that the QT interval prolongation per se  is not the crucial pathology in LQTS. The delayed cellular repolarization in LQTS represents either impaired rapid or slow delayed rectifier potassium currents (iKr or iKs) or inappropriately inactivated sodium currents (iNa). The main arrhythmogenic substrate resulting from these altered ion currents is an increase in transmural repolarization heterogeneity. This heterogeneity favors the development of torsade de pointes, which is triggered by early after-depolarizations. More than 300 mutations in six genes encoding cardiac ion channel subunits and ankyrin B have been identified in patients with LQTS. According to the affected ion channel subunit, LQTS is classified into six subtypes with partially different clinical courses and triggers of torsade de pointes. Hence, the clinical and electrophysiologic presentations of the syndrome are considerably heterogeneous, and the effects of different drugs may be unpredictable.

The QT interval obtained by a 12-lead electrocardiogram is only a rough measure of the repolarization time. Diagnosis based solely on summation vectors projected to the body surface is therefore neither sensitive nor specific. Accordingly, studies that only focus on drug effects on the QT interval may produce premature conclusions regarding potential safety or risk of these drugs in LQTS. This explains the contradicting results of numerous investigations, which report different effects of drugs on QT interval. Kies et al.  recommend isoflurane as volatile anesthetic of choice in LQTS patients. In our opinion, to date, such recommendation cannot be supported. The reported effects of volatile anesthetics on QT interval are inconsistent or even conflicting. Only few studies have focused on QT heterogeneity or ion channel physiology, and it seems that all volatile anesthetics—including isoflurane—interact directly with cardiac delayed rectifier potassium channels.8,,9,,10,,11 We therefore propose to avoid this class of anesthetics and would prefer propofol as the anesthetic of choice until more information is available from pharmacologic studies that focus on ion channel physiology and transmural heterogeneity of repolarization. These studies should ideally differentiate between LQTS subtypes.

*University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany. stefan.rasche@uniklinikum-dresden.de

Kies JS, Pabelick CM, Hurley HA, White RD, Ackerman MJ: Anesthesia for patients with congenital long QT syndrome. Anesthesiology 2005; 102:204–10
Roden DM, Lazzara R, Rosen M, Schwartz P, Towbin J, Vincent GM: Multiple mechanisms in the long-QT-syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94:1996–2012
Antzelevitch C: Cellular basis and mechanisms underlying normal and abnormal myocardial repolarization and arrhythmogenesis. Ann Med 2004, 36 (suppl 1):5–14
Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes. Circulation 2000; 102:1178–85
Mohler JP, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, du Bellk WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogersk TB, Lederer WJ, Escande D, Le Marec H, Bennett V: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421:634–9
Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Prioi SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ: Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998; 339:960–5
Vincent GM, Timothy KW, Leppert M, Keating M: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327:846–52
Suzuki A, Bosniak ZJ, Kwok WM: The effects of isoflurane on the cardiac slowly activating delayed-rectifier potassium channel in guinea pig ventricular myocytes. Anesth Analg 2003; 96:1308–15
Chen X, Yamakage M, Yamada Y, Tohse N, Namiki A: Inhibitory effects of volatile anesthetics on currents produced on heterologous expression of KvLQT1 and minK in Xenopus oocytes. Vascul Pharmacol 2002; 39:33–8
Weissenburger J, Nesterenk VV, Antzelevitch C: Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo. J Cardiovasc Electrophysiol 2000; 11:290–304
Takahara A, Sugiyama A, Satoh Y, Wang K, Honsho S, Hashimoto K: Halothane sensitizes the canine heart to pharmacological IKr blockade. Eur J Pharmacol 2005; 507:169–77